IDEAS home Printed from https://ideas.repec.org/a/spr/eujhec/v26y2025i3d10.1007_s10198-024-01706-x.html
   My bibliography  Save this article

An assessment of the implications of distribution remuneration and taxation policies on the final prices of prescription medicines: evidence from 35 countries

Author

Listed:
  • Giovanny Leon

    (Novartis Pharma AG)

  • Christophe Carbonel

    (Novartis Pharma AG)

  • Aparajit Rampuria

    (Novartis Pharma AG)

  • Ravindra Singh Rajpoot

    (Novartis Healthcare Private Limited)

  • Parth Joshi

    (Novartis Healthcare Private Limited)

  • Panos Kanavos

    (Department of Health Policy and Medical Technology Research Group-LSE Health, The London School of Economics and Political Science)

Abstract

This paper analyses the structure of and variability in taxation and prescription drug distribution policies and quantifies the impact of such policies on the cost of prescription drugs to health systems in 35 countries. Taxes on prescription drugs remain highly prevalent (83% of the sample) although 63% of the sample countries implement a lower than standard VAT rate. Three remuneration types of the wholesale and retail distribution chain have been identified. Wholesale and retail distributors are remunerated on a regressive mark-up basis, which is price-dependent, although fixed fees and fixed percentages, which are non-price dependent, are also highly prevalent. Price component analysis for three groups of products classed as high-, medium- and low-priced suggests that mark-ups plus taxes varied significantly across countries and products, and ranged from 5% to 187% of ex-factory prices. Average margins also vary significantly by countries and products ranging 5–65% of retail prices. The cost of distribution and taxation contributes significantly to prescription drug costs for health systems. Although distribution chain remuneration raises efficiency and overall affordability questions, these need to be considered together with the regulatory framework shaping market structure of the distribution chain, as well as any prevailing horizontal and vertical integration policies. The overall cost of prescription drugs could be reduced immediately by eliminating taxation; this could go some way to alleviate fiscal pressures on health budgets, whilst avoiding resource re-allocation from health to other sectors.

Suggested Citation

  • Giovanny Leon & Christophe Carbonel & Aparajit Rampuria & Ravindra Singh Rajpoot & Parth Joshi & Panos Kanavos, 2025. "An assessment of the implications of distribution remuneration and taxation policies on the final prices of prescription medicines: evidence from 35 countries," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 26(3), pages 513-536, April.
  • Handle: RePEc:spr:eujhec:v:26:y:2025:i:3:d:10.1007_s10198-024-01706-x
    DOI: 10.1007/s10198-024-01706-x
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s10198-024-01706-x
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.

    File URL: https://libkey.io/10.1007/s10198-024-01706-x?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Garattini, Livio & Motterlini, Nicola & Cornago, Dante, 2008. "Prices and distribution margins of in-patent drugs in pharmacy: A comparison in seven European countries," Health Policy, Elsevier, vol. 85(3), pages 305-313, March.
    2. Boris Kaiser & Christian Schmid, 2016. "Does Physician Dispensing Increase Drug Expenditures? Empirical Evidence from Switzerland," Health Economics, John Wiley & Sons, Ltd., vol. 25(1), pages 71-90, January.
    3. Srivastava, Divya & McGuire, Alistair, 2014. "Analysis of prices paid by low-income countries: how price sensitive is government demand for medicines?," LSE Research Online Documents on Economics 60341, London School of Economics and Political Science, LSE Library.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Leon, Giovanny & Carbonel, Christophe & Rampuria, Aparajit & Singh Rajpoot, Ravindra & Joshi, Parth & Kanavos, Panos, 2025. "An assessment of the implications of distribution remuneration and taxation policies on the final prices of prescription medicines: evidence from 35 countries," LSE Research Online Documents on Economics 124243, London School of Economics and Political Science, LSE Library.
    2. Alexander Ahammer & Ivan Zilic, 2017. "Do Financial Incentives Alter Physician Prescription Behavior? Evidence from Random Patient-GP Allocations," Working Papers 1701, The Institute of Economics, Zagreb.
    3. Stacherl, Barbara & Renner, Anna-Theresa & Weber, Daniela, 2023. "Financial incentives and antibiotic prescribing patterns: Evidence from dispensing physicians in a public healthcare system," Social Science & Medicine, Elsevier, vol. 321(C).
    4. Olivia Bodnar & Hugh Gravelle & Nils Gutacker & Annika Herr, 2024. "Financial incentives and prescribing behavior in primary care," Health Economics, John Wiley & Sons, Ltd., vol. 33(4), pages 696-713, April.
    5. Fabienne Loetscher, Christian P.R. Schmid, Michael Gerfin, "undated". "The effect of higher out-of-pocket payments on drug prices and demand," Diskussionsschriften dp2405, Universitaet Bern, Departement Volkswirtschaft.
    6. Dean T. Jamison & Hellen Gelband & Susan Horton & Prabhat Jha & Ramanan Laxminarayan & Charles N. Mock & Rachel Nugent, 2017. "Disease Control Priorities, Third Edition," World Bank Publications - Books, The World Bank Group, number 28877, April.
    7. Mareike Heimeshoff & Helge Hollmeyer & Jonas Schreyögg & Oliver Tiemann & Doris Staab, 2012. "Cost of Illness of Cystic Fibrosis in Germany," PharmacoEconomics, Springer, vol. 30(9), pages 763-777, September.
    8. Chi Shen & Qiwei Deng & Sha Lai & Liu Yang & Dantong Zhao & Yaxin Zhao & Zhongliang Zhou, 2024. "New evidence on supplier-induced demand in China’s public tertiary hospitals: is the cost of hospitalization higher in the off-season?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 25(6), pages 951-962, August.
    9. Daniel Burkhard & Christian P. R. Schmid & Kaspar Wüthrich, 2019. "Financial incentives and physician prescription behavior: Evidence from dispensing regulations," Health Economics, John Wiley & Sons, Ltd., vol. 28(9), pages 1114-1129, September.
    10. Rachamin, Yael & Meier, Rahel & Valeri, Fabio & Rosemann, Thomas & Muheim, Leander, 2021. "Physician-dispensing as a determinant of clinical and process measurements in patients at increased cardiovascular risk: A cross-sectional study in Swiss general practice," Health Policy, Elsevier, vol. 125(10), pages 1305-1310.
    11. Müller, Tobias & Schmid, Christian & Gerfin, Michael, 2023. "Rents for Pills: Financial incentives and physician behavior," Journal of Health Economics, Elsevier, vol. 87(C).
    12. Ben Greiner & Le Zhang & Chengxiang Tang, 2017. "Separation of prescription and treatment in health care markets: A laboratory experiment," Health Economics, John Wiley & Sons, Ltd., vol. 26(S3), pages 21-35, December.
    13. Luke Connelly & Gianluca Fiorentini & Marica Iommi, 2022. "Supply-side solutions targeting demand-side characteristics: causal effects of a chronic disease management program on adherence and health outcomes," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 23(7), pages 1203-1220, September.
    14. Boris Kaiser, 2017. "Gender-specific practice styles and ambulatory health care expenditures," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 18(9), pages 1157-1179, December.
    15. Wang, Fan & Xu, Danni & Zhuo, Xiaopo & Zhang, Chao & Liu, Yaoqi, 2022. "Improving consumer welfare in vaccine market: Pricing, government subsidies and consumer awareness," Transportation Research Part E: Logistics and Transportation Review, Elsevier, vol. 167(C).
    16. Livio Garattini & Alessandro Curto & Anna Padula, 2016. "Reimbursable drug classes and ceilings in Italy: why not only one?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 17(8), pages 923-926, November.
    17. Ye Shing Lourdes Loh & Audrey K L Siah & Sharon G M Koh & Wing Loong Cheong & Tin Tin Su, 2023. "”What’s up with price controls?” Stakeholders’ views on the regulation of pharmaceutical pricing in Malaysia," PLOS ONE, Public Library of Science, vol. 18(12), pages 1-18, December.
    18. Lagarde, Mylène & Blaauw, Duane, 2022. "Overtreatment and benevolent provider moral hazard: Evidence from South African doctors," Journal of Development Economics, Elsevier, vol. 158(C).
    19. Hjalmarsson, Linn & Schmid, Christian P.R. & Schreiner, Nicolas, 2024. "A Prescription for Knowledge: Patient Information and Generic Substitution," Working papers 2024/05, Faculty of Business and Economics - University of Basel.
    20. Zhou, Cuihua & Hao, Yifei & Lan, Yanfei & Li, Weifeng, 2023. "To introduce or not? Strategic analysis of hospital operations with telemedicine," European Journal of Operational Research, Elsevier, vol. 304(1), pages 292-307.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:eujhec:v:26:y:2025:i:3:d:10.1007_s10198-024-01706-x. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.